Aprea Therapeutics files for IPO

|About: Aprea Therapeutics (APRE)|By:, SA News Editor

Clinical-stage biopharma Aprea Therapeutics has filed for an initial public offering.

The filing comes via J.P. Morgan, Morgan Stanley, and RBC Capital Markets, with a placeholder registration for $86.25M.

It's seeking a Nasdaq listing under the symbol APRE.

Operating expenses for the six months ended June 30 were $10.35M. The company expects IPO proceeds and cash on hand to complete each of its ongoing clinical trials.

Subscribe for full text news in your inbox